Price (90d)
No price history yet — the daily price refresh runs once a day.
Signal Score (90d)
100Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2026 | $320.17M | $-36.74M | $-0.88 |
| 2025 | $292.50M | $-33.99M | $-0.83 |
| 2024 | $303.91M | $-184.35M | $-4.59 |
| 2023 | $338.75M | $-52.44M | $-1.33 |
| 2022 | $316.22M | $-26.55M | $-0.68 |
Social Signal Score
Earnings
Thu, Oct 1(in 7 weeks)
Consensus estimate $-0.10 per share
Typical surprise +36.4% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Jul 14$-0.07 vs $-0.11beat
- Thu, Apr 2$-0.07 vs $-0.11beat
- Tue, Jan 6$-0.15 vs $-0.10miss
- Thu, Oct 2$-0.10 vs $-0.14beat
- Tue, Jul 15$-0.03 vs $-0.13beat
- Wed, Apr 2$0.03 vs $-0.13beat
Estimates and results for ANGO via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
ANGOhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Mentions (2)
- Newszacks.com·2d ago·Neutral
AngioDynamics (ANGO) Up 8.9% Since Last Earnings Report: Can It Continue? AngioDynamics (ANGO) reported earnings 30 days ago. What's next for the stock?
View source ↗ - Newsmarketbeat.com·3d ago·Neutral
AngioDynamics Sees MedTech Becoming Majority of Revenue in Fiscal 2027 AngioDynamics NASDAQ: ANGO expects its MedTech business to become the majority of company revenue in fiscal 2027, as the company continues a multiyear shift away from slower-growth legacy markets and toward higher-growth medical technology platforms, executives said during a Canaccord fireside chat.
View source ↗